LEADER

Nancy A. Dreyer, MPH, PhD, FISPE
Chief of Scientific Affairs
Outcome
Cambridge, MA

COORDINATORS

Michelle Leavy, MPH
Sr. Research Associate, Scientific Affairs
Outcome
Cambridge, MA

Pattra Wirojratana Mattox, MSc
Research Associate, Scientific Affairs
Outcome
Cambridge, MA

COLLABORATORS

Marc L. Berger, MD
VP, Global Health Outcomes
Eli Lilly and Company
Indianapolis, IN

Jesse Berlin, ScD
VP, Pharmacoepidemiology
Johnson & Johnson Pharmaceutical R&D
Titusville, NJ

Michael N. Cook, PhD, MSc, MSPH
Director, Epidemiology
Global Safety Surveillance & Epidemiology
Pfizer
Collegeville, PA

Richard Gliklich, MD
President
Outcome
Cambridge, MA

Ken Hornbuckle, DVM, PhD
Sr. Epidemiology Advisor
Risk Management & Pharmacoepidemiology
Global Patient Safety
Eli Lilly and Company
Indianapolis, IN

Barbara J. McNeil, PhD, MD
Head, Dept. of Health Care Policy
Harvard Medical School
Boston, MA

Stephen Motsko PharmD, PhD
Sr. Epidemiology Scientist
Risk Management & Pharmacoepidemiology
Global Patient Safety
Eli Lilly and Company
Indianapolis, IN

Dan Ollendorf, MPH
Chief Review Officer
Institute for Clinical & Economic Review
Boston, MA

John Parkinson, PhD
Director
General Practitioners Research Database
London, United Kingdom

Sebastian Schneeweiss, MD, ScD
Assoc. Professor of Medicine & Epidemiology
Harvard Medical School
Vice Chief, Pharmacoepidemiology &
Pharmacoeconomics, Dept. of Medicine
Brigham & Women's Hospital
Boston, MA

Daniel E. Singer, MD
Professor of Medicine, Harvard Medical School
Director, Clinical Epidemiology
Unit and Research Fellowship Program
MGH General Medicine Division
Director, Epidemiology, Outcomes, and Disease
Management Unit
MGH Clinical Research Program
Boston, MA

Til Stürmer, MD, MPH
Associate Professor and Director
Department of Epidemiology
University of North Carolina
School of Public Health
Chapel Hill, NC

Alexander M. Walker, MD, PhD
Principal
Whiscon
Wellesley, MA

Douglas J. Watson, PhD
Senior Director, Medical/Scientific Liaison
Merck Research Laboratories
North Wales, PA

SUPPORTERS

José Luis Alloza, MD, PhD
Director, Alcalá Clinical Pharmacology
Project for Drug R&D
Universtiy of Alcalá
Madrid, Spain

G. Lawrence Atkins, PhD
Executive Director
Public Policy & Reimbursement
Schering-Plough Corporation
Washington, DC

Christina Farup, MD, MS
VP, Evidence Based Medicine
Novartis Pharmaceuticals Corporation
Hanover, NJ

Joy Frestedt, PhD, RAC, CCTI
President & CEO
Frestedt, Inc.
St. Louis Park, MN

Sarah Garner, PhD
Associate Director, R&D
National Institute for Health and Clinical Excellence
London, England

R.M.C. Herings, PharmD, MPH, PhD, FISPE
Director, PHARMO Institute
Assoc. Professor of Pharmacoepidemiology
Dept. of Health Policy & Management
Erasmus MC
Rotterdam, The Netherlands

International Society of Pharmacoepidemiology
Bethesda, MD

Mark V. Johnston, PhD
Professor, Occupational Therapy
University of Wisconsin-Milwaukee
Milwaukee, WI

Kristijan Kahler Ph.D., R.Ph
Director, HE&OR, ABGU & NS
Evidence Based Medicine
Novartis Pharmaceuticals Corporation
East Hanover, NJ

Rob Mechanic, MBA
Executive Director, The Health Industry Forum
The Heller School of Social Policy and Management
Brandeis University
Waltham, MA

Jeff Schein, DrPH, MPH
Sr. Director, Outcomes Research
Internal Medicine
Ortho-McNeil Janssen Scientific Affairs
Raritan, NJ

Robin Seitzman, MPH, PhD
Director of Epidemiology
Outcome
Cambridge, MA

Hemal Shah, PharmD
Exec. Director, Health Economics &
Outcomes Research
Boehringer Ingelheim Pharmaceuticals, Inc
Ridgefield, CT

J. Michael Sprafka, MPH, PhD
Vice President
Kendle Consulting
Cincinnati, OH